메뉴 건너뛰기




Volumn 34, Issue 5, 2016, Pages e38-e40

Ruxolitinib enhances platelet production in patients with thrombocytopenic myelofibrosis

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FEDRATINIB; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2; LESTAURTINIB; PEGINTERFERON; PREDNISONE; RECOMBINANT INTERFERON; RUXOLITINIB; THALIDOMIDE; JAK2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

EID: 84958973171     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.0057     Document Type: Article
Times cited : (11)

References (10)
  • 2
    • 77956696835 scopus 로고    scopus 로고
    • Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
    • Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010
    • (2010) N Engl J Med , vol.363 , pp. 1117-1127
    • Verstovsek, S.1    Kantarjian, H.2    Mesa, R.A.3
  • 3
    • 84863393110 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    • Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
    • (2012) N Engl J Med , vol.366 , pp. 799-807
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 4
    • 84865192181 scopus 로고    scopus 로고
    • Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls
    • Verstovsek S, Kantarjian HM, Estrov Z, et al: Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood 120:1202-1209, 2012
    • (2012) Blood , vol.120 , pp. 1202-1209
    • Verstovsek, S.1    Kantarjian, H.M.2    Estrov, Z.3
  • 5
    • 84876790720 scopus 로고    scopus 로고
    • The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, phase III study in patients with myelofibrosis
    • Verstovsek S, Mesa RA, Gotlib J, et al: The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, phase III study in patients with myelofibrosis Br J Haematol 161:508-516, 2013
    • (2013) Br J Haematol , vol.161 , pp. 508-516
    • Verstovsek, S.1    Mesa, R.A.2    Gotlib, J.3
  • 6
    • 33947541141 scopus 로고    scopus 로고
    • Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth
    • Li Z, Xu M, Xing S, et al: Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 282:3428-3432, 2007
    • (2007) J Biol Chem , vol.282 , pp. 3428-3432
    • Li, Z.1    Xu, M.2    Xing, S.3
  • 7
    • 80052441368 scopus 로고    scopus 로고
    • JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients
    • Panova-Noeva M, Marchetti M, Buoro S, et al: JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 118:2599-2601, 2011
    • (2011) Blood , vol.118 , pp. 2599-2601
    • Panova-Noeva, M.1    Marchetti, M.2    Buoro, S.3
  • 8
    • 0012889254 scopus 로고    scopus 로고
    • A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    • Mesa RA, Steensma DP, Pardanani A, et al: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534-2541, 2003
    • (2003) Blood , vol.101 , pp. 2534-2541
    • Mesa, R.A.1    Steensma, D.P.2    Pardanani, A.3
  • 9
    • 84878233090 scopus 로고    scopus 로고
    • Expand: A phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 - 109/L and 99 - 109/L
    • abstr 177
    • Harrison CN, Gisslinger H, Miller CB, et al: Expand: A phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 - 109/L and 99 - 109/L. Blood 120, 2012 (abstr 177)
    • (2012) Blood , vol.120
    • Harrison, C.N.1    Gisslinger, H.2    Miller, C.B.3
  • 10
    • 84878259462 scopus 로고    scopus 로고
    • Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 - 109/L): A comparison to patients with normal or high starting platelet counts
    • abstr 176
    • Talpaz M, Paquette R, Afrin L, et al: Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 - 109/L): A comparison to patients with normal or high starting platelet counts. Blood 120, 2012 (abstr 176)
    • (2012) Blood , vol.120
    • Talpaz, M.1    Paquette, R.2    Afrin, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.